Clinical trial
Voriconazole For Chronic Bronchopulmonary Aspergillosis
NCT00159822 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00159822 |
|---|---|
| Title | Voriconazole For Chronic Bronchopulmonary Aspergillosis |
| Official title | Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Aspergillosis |
| Intervention type | Drug |
| Interventions | Voriconazole |
| Enrollment | 48 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 20, 2010 |
| Countries | France |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: